Skip to main content
CivicGate

HR 8630
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

PEAT Act of 2026

To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.

Introduced Apr 30, 2026

Latest action (Apr 30, 2026) Referred to the House Committee on Energy and Commerce.

Referred to
Energy and Commerce Committee
Policy area
Health
Issues
Healthcare

Summary
  • Prohibits federal regulators from classifying a biologic drug as a "biological product" based solely on the presence of a clinically inactive protein
  • Makes a technical correction to the regulatory language governing biological product definitions

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)
11 cosponsors

Money behind the sponsor

Top reported contributors to Michael A. Rulli’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.

  • COMPCO $30,800
  • Employer not reported $24,468
  • CLEAN ENERGY FUTURE LLC $13,200
  • KIMBLE COMPANY $13,150
  • P.I. & I MOTOR EXPRESS $10,000

Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Michael A. Rulli → · Outside spending →

Actions (2)
  1. Apr 30, 2026 Referred to the House Committee on Energy and Commerce. · house
  2. Apr 30, 2026 Introduced in House

Similar bills (6)

Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.

  • HR 7366 — Dietary Supplement Regulatory Uniformity Act · Introduced Feb 4, 2026 · Cong. 119 65%
  • HR 9186 — Controlled Substances Act Clarification in Sciences Act of 2026 · Introduced Jun 8, 2026 · Cong. 119 64%
  • S 3325 — Expanding Access to Affordable Drugs and Medical Devices Act · Introduced Dec 3, 2025 · Cong. 119 61%
  • S 1830 — Right to Treat Act · Introduced Mar 19, 2026 · Cong. 119 61%
  • HR 6868 — ACCESS Through OTC Innovation Act · Introduced Dec 18, 2025 · Cong. 119 61%
  • HR 7980 — Protecting Americans from Unsafe Drugs Act of 2026 · Introduced Mar 18, 2026 · Cong. 119 61%

Text versions (1)
  • Introduced in House · Apr 30, 2026

Only one text version is on file, so there’s no earlier version to compare against yet.

Full text

IN THE HOUSE OF REPRESENTATIVES

April 30, 2026

Mr. Rulli (for himself and Mrs. Harshbarger) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Protecting Equal Access to Thyroid Act of 2026” or the “PEAT Act of 2026”.

SEC. 2. PROHIBITION WITH RESPECT TO TREATMENT OF PROTEINS IN BIOLOGICS.

(a) In General.—Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)) is amended—

(1) by striking “The term” and inserting the following:

“(A) The term”; and

(2) by adding at the end the following:

“(B) A biologic described in subparagraph (A) may not be treated as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic.”.

(b) Technical Correction.—Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)) is amended in subparagraph (A), as designated by subsection (a)(1), by striking “protein ,” and inserting “protein,”. <all>

Comments

Comments

Loading comments…